FDA advisers narrowly vote to add six peptides to a drug compounding list
The close vote could open the door for compounded versions of popular peptide therapies, a closely watched front in the GLP-1 supply battle.
Read at The American Journal of Managed Care →Full coverage · 8 outlets
- The American Journal of Managed Care · lead
- PBSWATCH: FDA advisory panel narrowly backs use of several peptides favored by RFK Jr.
- RAPSFDA advisory committee backs two more peptides, rejects one for compounding list
- STATFDA advisory panel narrowly rejects compounding of one peptide, backs two others
- Partnership for Safe MedicinesJuly 27, 2026: FDA peptide panel narrowly votes to add unapproved drugs to compounding list
- Health AffairsFDA Advisory Committee’s Vote May Open A Drug-Compounding Back Door For Unapproved Peptides
- Pharmaceutical ExecutiveFDA Panel Votes to Loosen Restrictions for Four Peptides
- ThehillFDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists